---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-056875"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T21:38:23.399918+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ocugen signs binding term sheet to license OCU400 gene therapy in Korea; up to $11M upfront & milestones

## Summary
- Upfront license fees and near-term development milestones up to $11M.
- Sales milestones of $1M per $15M net sales in Korea (or $150M+ in first 10 years).
- Royalty of 25% on net sales; Ocugen to manufacture and supply OCU400.
- Estimated 15,000 RP patients in Korea; definitive agreement expected within 60 days.
- OCU400 in Phase 3 with target BLA filing mid-2026.

## SEC filing metadata
- accession: 0001104659-25-056875
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465925056875/0001104659-25-056875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465925056875/tm2517307d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-056875
- JSON: https://secwatch.observer/filing/0001104659-25-056875.json
- Plain text: https://secwatch.observer/filing/0001104659-25-056875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.